MV4;11 |
cytotoxicity assay |
~100 μM |
|
DMSO |
IC50=26 nM |
21964340 |
RS4;11 |
cytotoxicity assay |
~100 μM |
|
DMSO |
IC50=192 nM |
21964340 |
MOLM13 |
cytotoxicity assay |
~100 μM |
|
DMSO |
IC50=120 nM |
21964340 |
NOMO1 |
cytotoxicity assay |
~100 μM |
|
DMSO |
IC50=15 nM |
21964340 |
HEL |
cytotoxicity assay |
~100 μM |
|
DMSO |
IC50=1 μM |
21964340 |
K562 |
cytotoxicity assay |
~100 μM |
|
DMSO |
IC50>100 μM |
21964340 |
MEG01 |
cytotoxicity assay |
~100 μM |
|
DMSO |
IC50=25 μM |
21964340 |
HL60 |
cytotoxicity assay |
~100 μM |
|
DMSO |
IC50=890 nM |
21964340 |
MV4;11 |
Apoptosis assay |
~100 μM |
|
DMSO |
induces apoptosis |
21964340 |
MOLM13 |
Apoptosis assay |
~100 μM |
|
DMSO |
induces apoptosis |
21964340 |
MV4;11 |
Function assay |
|
|
DMSO |
decreases the recruitment of BRD3/4 and impaired recruitment of CDK9 and PAF1 to the transcriptional start site |
21964340 |
PBMC |
Function assay |
|
|
DMSO |
inhibits IL-6 with pIC50 of 6.7 |
22437115 |
A2 |
Function assay |
~10 μM |
|
DMSO |
reactivates latent HIV-1 |
23255218 |
A72 |
Function assay |
~10 μM |
|
DMSO |
reactivates latent HIV-1 |
23255218 |
BC1 |
Growth inhibitory assay |
~1 μM |
|
DMSO |
IC50=220 nM |
23792448 |
BC3 |
Growth inhibitory assay |
~1 μM |
|
DMSO |
IC50=460 nM |
23792448 |
BCBL1 |
Growth inhibitory assay |
~1 μM |
|
DMSO |
IC50=330 nM |
23792448 |
BJAB |
Growth inhibitory assay |
~1 μM |
|
DMSO |
IC50=970 nM |
23792448 |
Namalwa |
Growth inhibitory assay |
~1 μM |
|
DMSO |
IC50=970 nM |
23792448 |
Jurkat |
Growth inhibitory assay |
~1 μM |
|
DMSO |
IC50=1220 nM |
23792448 |
MM1S |
Growth inhibitory assay |
~1 μM |
|
DMSO |
IC50=760 nM |
23792448 |
U266 |
Growth inhibitory assay |
~1 μM |
|
DMSO |
IC50=950 nM |
23792448 |
UM-PEL-1 |
Growth inhibitory assay |
~1 μM |
|
DMSO |
IC50=210 nM |
23792448 |
UM-PEL-3 |
Growth inhibitory assay |
~1 μM |
|
DMSO |
IC50=180 nM |
23792448 |
BC1 |
Function assay |
500 nM |
|
DMSO |
induces cell-cycle arrest |
23792448 |
BC3 |
Function assay |
500 nM |
|
DMSO |
induces cell-cycle arrest |
23792448 |
BC1 |
Function assay |
800 nM |
|
DMSO |
reduces c-Myc protein levels |
23792448 |
BC3 |
Function assay |
800 nM |
|
DMSO |
reduces c-Myc protein levels |
23792448 |
H929 |
Function assay |
~1 μM |
|
DMSO |
induces cell cycle arrest |
24335499 |
KMS12PE |
Function assay |
~1 μM |
|
DMSO |
induces cell cycle arrest |
24335499 |
KMS12BM |
Function assay |
~1 μM |
|
DMSO |
induces cell cycle arrest |
24335499 |
KMS18 |
Function assay |
~1 μM |
|
DMSO |
induces cell cycle arrest |
24335499 |
KMS11 |
Function assay |
~1 μM |
|
DMSO |
induces cell cycle arrest |
24335499 |
RPMI8226 |
Function assay |
~1 μM |
|
DMSO |
induces cell cycle arrest |
24335499 |
H929 |
Apoptosis assay |
~1 μM |
|
DMSO |
induces cell apoptosis |
24335499 |
KMS12PE |
Apoptosis assay |
~1 μM |
|
DMSO |
induces cell apoptosis |
24335499 |
KMS12BM |
Apoptosis assay |
~1 μM |
|
DMSO |
induces cell apoptosis |
24335499 |
KMS18 |
Apoptosis assay |
~1 μM |
|
DMSO |
induces cell apoptosis |
24335499 |
KMS11 |
Apoptosis assay |
~1 μM |
|
DMSO |
induces cell apoptosis |
24335499 |
RPMI8226 |
Apoptosis assay |
~1 μM |
|
DMSO |
induces cell apoptosis |
24335499 |
U87MG |
Function assay |
~10 μM |
|
DMSO |
reduces U87MG cellular ATP with IC50 of 1.05 μM |
24496381 |
A172 |
Function assay |
~10 μM |
|
DMSO |
reduces cellular ATP with IC50 of 1.28 μM |
24496381 |
SW1783 |
Function assay |
~10 μM |
|
DMSO |
reduces cellular ATP with IC50 of 2.68 μM |
24496381 |
U87MG |
Function assay |
~10 μM |
|
DMSO |
increases proportion of cells in the G1/S transition |
24496381 |
RAW267.4 |
Function assay |
1 μM |
|
DMSO |
reduces IL-6 production induced by LPS |
24859008 |
RAW267.4 |
Function assay |
1 μM |
|
DMSO |
reduces the association between BRD4 and acetylated p65 |
24859008 |
Me007 |
Growth inhibitory assay |
~100 μM |
|
DMSO |
inhibits the growth |
24906137 |
SK-Mel-28 |
Growth inhibitory assay |
~100 μM |
|
DMSO |
inhibits the growth |
24906137 |
Mel-RMU |
Growth inhibitory assay |
~100 μM |
|
DMSO |
inhibits the growth |
24906137 |
Mel-JD |
Growth inhibitory assay |
~100 μM |
|
DMSO |
inhibits the growth |
24906137 |
Mel-RM |
Growth inhibitory assay |
~100 μM |
|
DMSO |
inhibits the growth |
24906137 |
Me007 |
Apoptosis assay |
~100 μM |
|
DMSO |
induces apoptosis |
24906137 |
SK-Mel-28 |
Apoptosis assay |
~100 μM |
|
DMSO |
induces apoptosis |
24906137 |
Mel-RMU |
Apoptosis assay |
~100 μM |
|
DMSO |
induces apoptosis |
24906137 |
Mel-JD |
Apoptosis assay |
~100 μM |
|
DMSO |
induces apoptosis |
24906137 |
Mel-RM |
Apoptosis assay |
~100 μM |
|
DMSO |
induces apoptosis |
24906137 |
Me007 |
Function assay |
10 μM |
|
DMSO |
induces cell cycle arrest by upregulation of p21 |
24906137 |
SK-Mel-28 |
Function assay |
10 μM |
|
DMSO |
induces cell cycle arrest by upregulation of p21 |
24906137 |
Mel-RMU |
Function assay |
10 μM |
|
DMSO |
induces cell cycle arrest by upregulation of p21 |
24906137 |
Mel-JD |
Function assay |
10 μM |
|
DMSO |
induces cell cycle arrest by upregulation of p21 |
24906137 |
Mel-RM |
Function assay |
10 μM |
|
DMSO |
induces cell cycle arrest by upregulation of p21 |
24906137 |
Me007 |
Function assay |
10 μM |
|
DMSO |
upregulates proapoptotic and cell cycle arrest genes |
24906137 |
SK-Mel-28 |
Function assay |
10 μM |
|
DMSO |
upregulates proapoptotic and cell cycle arrest genes |
24906137 |
Mel-RMU |
Function assay |
10 μM |
|
DMSO |
upregulates proapoptotic and cell cycle arrest genes |
24906137 |
Mel-JD |
Function assay |
10 μM |
|
DMSO |
upregulates proapoptotic and cell cycle arrest genes |
24906137 |
Mel-RM |
Function assay |
10 μM |
|
DMSO |
upregulates proapoptotic and cell cycle arrest genes |
24906137 |
HepG2 |
Function assay |
|
18 hrs |
|
Upregulation of ApoA1 expression in human HepG2 cells assessed as concentration required to increase 70% of luciferase activity after 18 hrs by luciferase reporter gene assay, EC170 = 0.09 μM. |
22386529 |
Raji |
Function assay |
|
4 hrs |
|
Inhibition of BRD4 in human Raji cells assessed as reduction of MYC expression after 4 hrs, IC50 = 0.13 μM. |
24900758 |
MV4-11 |
Growth inhibition assay |
|
72 hrs |
|
Growth inhibition of human MV4-11 cells after 72 hrs by SRB assay, IC50 = 0.119 μM. |
25559428 |
MM1S |
Growth inhibition assay |
|
72 hrs |
|
Growth inhibition of human MM1S cells after 72 hrs by SRB assay, IC50 = 0.299 μM. |
25559428 |
HT-29 |
Growth inhibition assay |
|
72 hrs |
|
Growth inhibition of human HT-29 cells after 72 hrs by SRB assay, IC50 = 0.945 μM. |
25559428 |
Rosetta2 DE3 |
Function assay |
|
30 mins |
|
Displacement of FAM-labeled ZBA248 from BRD4 BD1 (44 to 168 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay, IC50 = 0.0317 μM. |
26080064 |
MV4-11 |
Cytotoxicity assay |
|
4 days |
|
Cytotoxicity against human MV4-11 cells harboring MLL1 fusion gene assessed as growth inhibition after 4 days by CellTiter-Glo luminescent assay, IC50 = 0.162 μM. |
26080064 |
Rosetta2 DE3 |
Function assay |
|
30 mins |
|
Displacement of FAM-labeled ZBA248 from BRD4 BD2 (333 to 460 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay, IC50 = 0.226 μM. |
26080064 |
MOLM13 |
Cytotoxicity assay |
|
4 days |
|
Cytotoxicity against human MOLM13 cells harboring MLL1 fusion gene assessed as growth inhibition after 4 days by CellTiter-Glo luminescent assay, IC50 = 0.228 μM. |
26080064 |
Rosetta2 DE3 |
Function assay |
|
30 mins |
|
Inhibition of FAM-labeled ZBA248 binding to recombinant human N-terminal His6-tagged BRD4 bromodomain 1 (44 to 168 residues) expressed in Rosetta2 DE3 cells after 30 mins by Flourescence polarization assay, IC50 = 0.0317 μM. |
28463487 |
MV4-11 |
Growth inhibition assay |
|
4 days |
|
Growth inhibition of human MV4-11 cells after 4 days by WST-8 assay, IC50 = 0.162 μM. |
28463487 |
Rosetta2 DE3 |
Function assay |
|
30 mins |
|
Inhibition of FAM-labeled ZBA248 binding to recombinant human N-terminal His6-tagged BRD4 bromodomain 2 (333 to 460 residues) expressed in Rosetta2 DE3 cells after 30 mins by Flourescence polarization assay, IC50 = 0.226 μM. |
28463487 |
MOLM13 |
Growth inhibition assay |
|
4 days |
|
Growth inhibition of human MOLM13 cells after 4 days by WST-8 assay, IC50 = 0.228 μM. |
28463487 |
Rosetta2 DE3 |
Function assay |
|
|
|
Binding affinity to biotinylated BRD3 BD1 (24 to 144 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method, Kd = 0.0298 μM. |
26080064 |
Rosetta2 DE3 |
Function assay |
|
|
|
Binding affinity to biotinylated BRD3 BD2 (306 to 417 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method, Kd = 0.0405 μM. |
26080064 |
Rosetta2 DE3 |
Function assay |
|
|
|
Binding affinity to biotinylated BRD4 BD1 (44 to 168 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method, Kd = 0.0528 μM. |
26080064 |
Rosetta2 DE3 |
Function assay |
|
|
|
Binding affinity to biotinylated BRD2 BD1 (72 to 205 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method, Kd = 0.0548 μM. |
26080064 |
Rosetta2 DE3 |
Function assay |
|
|
|
Binding affinity to biotinylated BRD2 BD2 (349 to 460 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method, Kd = 0.0703 μM. |
26080064 |
Rosetta2 DE3 |
Function assay |
|
|
|
Binding affinity to biotinylated BRD4 BD2 (333 to 460 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method, Kd = 0.215 μM. |
26080064 |
Rosetta2 DE3 |
Function assay |
|
|
|
Binding affinity to biotinylated CREBBP (1043 to 1159 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method, Kd = 3.084 μM. |
26080064 |
Rosetta2 DE3 |
Function assay |
|
30 mins |
|
Displacement of FAM-labeled ZBA248 from BRD3 BD1 (24 to 144 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay, Ki = 0.0072 μM. |
26080064 |
Rosetta2 DE3 |
Function assay |
|
30 mins |
|
Displacement of FAM-labeled ZBA248 from BRD4 BD1 (44 to 168 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay, Ki = 0.009 μM. |
26080064 |
Rosetta2 DE3 |
Function assay |
|
30 mins |
|
Displacement of FAM-labeled ZBA248 from BRD2 BD1 (72 to 205 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay, Ki = 0.009 μM. |
26080064 |
Rosetta2 DE3 |
Function assay |
|
30 mins |
|
Displacement of FAM-labeled ZBA248 from BRD3 BD2 (306 to 417 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay, Ki = 0.0223 μM. |
26080064 |
Rosetta2 DE3 |
Function assay |
|
30 mins |
|
Displacement of FAM-labeled ZBA248 from BRD2 BD2 (349 to 460 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay, Ki = 0.0496 μM. |
26080064 |
Rosetta2 DE3 |
Function assay |
|
30 mins |
|
Displacement of FAM-labeled ZBA248 from BRD4 BD2 (333 to 460 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay, Ki = 0.0748 μM. |
26080064 |
Rosetta2 DE3 |
Function assay |
|
30 mins |
|
Inhibition of FAM-labeled ZBA248 binding to recombinant human N-terminal His6-tagged BRD4 bromodomain 1 (44 to 168 residues) expressed in Rosetta2 DE3 cells after 30 mins by Flourescence polarization assay, Ki = 0.009 μM. |
28463487 |
Rosetta2 DE3 |
Function assay |
|
30 mins |
|
Inhibition of FAM-labeled ZBA248 binding to recombinant human N-terminal His6-tagged BRD4 bromodomain 2 (333 to 460 residues) expressed in Rosetta2 DE3 cells after 30 mins by Flourescence polarization assay, Ki = 0.0748 μM. |
28463487 |
THP1 |
Antiinflammatory assay |
|
|
|
Antiinflammatory activity in human THP1 cells |
22386529 |
HT-29 |
Function assay |
0.3125 uM to 5 uM |
24 hrs |
|
Inhibition of BRD4 in human HT-29 cells assessed as reduction in c-Myc protein expression at 0.3125 uM to 5 uM uM after 24 hrs by Western blotting method |
25559428 |
MV4-11 |
Function assay |
|
|
|
Inhibition of BRD4 in human MV4-11 cells assessed as downregulation of BCL2 RNA expression by RNA-seq analysis |
29259751 |
MV4-11 |
Function assay |
|
|
|
Inhibition of BRD4 in human MV4-11 cells assessed as downregulation of cMYC RNA expression by RNA-seq analysis |
29259751 |
U-2 OS |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells |
29435139 |
A673 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells |
29435139 |
DAOY |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells |
29435139 |
BT-37 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells |
29435139 |
RD |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells |
29435139 |
SK-N-SH |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells |
29435139 |
BT-12 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells |
29435139 |
MG 63 (6-TG R) |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells |
29435139 |
NB1643 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells |
29435139 |
OHS-50 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells |
29435139 |
fibroblast cells |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells |
29435139 |
Rh41 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells |
29435139 |
Rh30 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells |
29435139 |
SJ-GBM2 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells |
29435139 |
SK-N-MC |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells |
29435139 |
NB-EBc1 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells |
29435139 |
LAN-5 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells |
29435139 |
Rh18 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells |
29435139 |